Dyspepsia Clinical Trial
— PIPPIOfficial title:
Smartphone App-assisted Discontinuation of Short-term PPI Treatment - an Feasibility Study
Proton pump inhibitors (PPIs) are frequently prescribed for 30 days but taken infinitely. PPIs belong to the most often inappropriate medicines (PIMs). Correct intake of medicines (named adherence) can be supported by digital devices such as smartphone applications. The goal of this interventional study is to test the feasibility of an app-based treatment support provided by community pharmacists in patients prescribed a short-term PPI (30 days). The intervention consists in tracking medication intake, symptom course and well-being over the treatment duration of 30 days with the mednet app on patients' personal smartphones.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 15, 2024 |
Est. primary completion date | October 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - is =18 years old; - has symptoms that suggest or correspond to gastroesophageal reflux disease (GERD); - is newly prescribed a short-term PPI treatment; - accepts to use of the smartphone app mednet during the study period; - signs the informed consent form; - understands and speaks (Swiss) German. Exclusion Criteria: - in the opinion of the pharmacist or physician, unlikely to comply with the study schedule or are unsuitable for any other reason. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Goldene Engel Apotheke | Basel | Basel-Stadt |
Switzerland | TopPharm Apotheke am Spalebärg | Basel | Basel-Stadt |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patients with PPI treatment over 30 days | Number of patients who started and stopped a PPI after 30 days | 30 days (treatment duration) | |
Secondary | Treatment extensions | Number of PPI treatment extensions including reasons and number of additional days | 30 days (treatment duration) | |
Secondary | Physicians' and pharmacists' satisfaction with the service | Physicians' and pharmacists satisfaction with the service including adherence report assessed through semi-structured interviews | 2 weeks after study completion | |
Secondary | Patients' satisfaction with the service | Patients' satisfaction with the service including the app assessed through semi-structured interviews | 2 weeks after the end of treatment | |
Secondary | Reliable diagnosis after PPI treatment | Number of reliable diagnosis after short-term PPI treatment including treatment extensions | After 30 days (treatment duration) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03941288 -
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
|
Phase 2 | |
Completed |
NCT04429802 -
The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Withdrawn |
NCT02863822 -
Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.
|
N/A | |
Recruiting |
NCT00978159 -
Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia
|
Phase 4 | |
Completed |
NCT00723502 -
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
|
Phase 2 | |
Terminated |
NCT00220844 -
Tricyclic Antidepressants (TCAs) on Gastric Emptying
|
N/A | |
Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
Completed |
NCT00148603 -
Montelukast in the Treatment of Duodenal Eosinophilia
|
N/A | |
Completed |
NCT00232037 -
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
|
Phase 3 | |
Completed |
NCT00110968 -
Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia
|
Phase 3 | |
Completed |
NCT00164996 -
Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia
|
Phase 3 | |
Completed |
NCT00232102 -
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
|
Phase 3 | |
Recruiting |
NCT05718960 -
Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia
|
N/A | |
Terminated |
NCT04247100 -
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
|
N/A | |
Completed |
NCT05750641 -
The Efficacy of Removal of Animal Milk From the Diet in Functional Dyspepsia: A Cross-sectional Study
|
||
Completed |
NCT03252743 -
ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study.
|
N/A | |
Completed |
NCT04697641 -
Helicobacter Pylori Eradication in Functional Dyspepsia
|
N/A | |
Recruiting |
NCT04918329 -
Functional Digestive Disorders Observatory
|
||
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 |